MedWatch

Dicerna CEO explains how a desire to expand collaborations turned into a potential acquisition

Novo Nordisk's possible billion-dollar takeover of US-based Dicerna, which was announced last week, stems from a suggestion to extend their partnership, CEO at Dicerna Douglas Fambrough tells MedWatch, and Novo Nordisk confirms.

What could end up being Novo Nordisk's biggest deal in recent times actually began as a wish to expand the collaboration with the US-based Dicerna around three months ago, says the latter company's CEO Douglas Fambrough.

Last week, Novo Nordisk unveiled the potential acquisition deal to the public, saying that the takeover's price tag would read USD 3.3bn.

Read the whole article

Get 14 days free access.
No credit card required.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

"Real world" patient data documents the long-term effects of ALK vaccines

In the largest study ever of its kind, patient data from the "real world" documents the long-term effects of up to nine years of ALK vaccines. Up until now, it has not been possible to demonstrate these in ordinary clinical studies where the follow-up period is shorter, and the new knowledge could be a turning point in ALK's dialog about prices and subsidies with authorities and payers. 

Further reading

Related articles

Latest news

See all jobs